Some of the ASX listed companies, during the market turmoil went under selling pressure. Now, these growing companies to invest in, with good fundamentals, are available at discounted prices.
Lovisa Holdings Limited (ASX: LOV)
Lovisa Holdings Limited reported solid growth for the first half of FY25, with revenue increasing by 8.8% to $405.9 million, driven largely by its expanding global store network. Gross margin improved significantly to 82.4%, contributing to a 10.7% rise in EBIT to $90.2 million and a 6.5% increase in net profit after tax to $56.9 million. Strong operating cash flow of $141.1 million supported a net cash position at the half-year mark, enabling the company to declare an unfranked interim dividend of 50 cents per share.
The company is among the high growth stocks having opened 57 new stores across 49 markets during the period, taking the total to 943, with Europe and Canada leading new store growth. Despite inflationary pressures and increased operational costs in higher-cost markets, profitability was supported by a significant reduction in CEO long-term incentive expenses and effective cost management.
Lovisa remains focused on further global expansion, with continued investment in store rollouts and infrastructure. Trading in early 2H FY25 showed strong momentum, with total sales up 12.9% and comparable store sales up 3.7%. The company’s balance sheet strength positions it well to sustain its growth trajectory and expand into its 50th market, Zambia, in the coming weeks.
Monash IVF Group Limited (ASX: MVF)
Monash IVF Group reported strong first-half FY25 results, with revenue rising 11.6% to $140.3 million and underlying EBITDA growing 10.7% to $35.6 million. Underlying NPAT increased by 5.5% to $15.8 million, in line with guidance. All core business segments, domestic assisted reproductive services (ARS), women’s imaging, and international ARS contributed to this growth.
In Australia, patient treatment volumes rose 4.7%, and market share for stimulated cycles increased by 0.6% to 21.5%, despite broader industry softness in key states. The company also welcomed 10 new fertility specialists and continued infrastructure investments, including the upcoming Brisbane clinic.
International operations performed strongly, with EBIT up 74% and notable growth in Malaysia (12.2% in stimulated cycles) and Singapore (7.9%), despite the disruption of relocating to a new clinic.
While net debt rose to $72.5 million, Monash IVF retains financial flexibility and expects FY25 underlying NPAT to land between $30.0 million and $31.0 million. Despite short-term sector volatility, the company remains optimistic due to strong long-term demand drivers such as genetics, egg freezing, and increased participation from diverse patient groups. Traditional and new demand drivers support long-term industry growth.
Monash IVF Group Limited had confirmed the occurrence of an incident at its Brisbane clinic. Monash IVF had notified its insurers and does not currently consider the incident as material to FY2025 financial performance
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
